{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:09:51Z","timestamp":1755216591538,"version":"3.43.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"DOI":"10.7759\/cureus.89339","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T14:34:39Z","timestamp":1754318079000},"source":"Crossref","is-referenced-by-count":0,"title":["Xywav: A Treatment Option for Idiopathic Hypersomnia in Down Syndrome"],"prefix":"10.7759","author":[{"given":"Serena","family":"Sanchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Xywav. Identifying idiopathic hypersomnia. (2024). Accessed: June 2, 2025: https:\/\/www.xywavhcp.com\/idiopathic-hypersomnia\/diagnosis\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsmc.2017.03.009","article-title":"Idiopathic hypersomnia","volume":"12","author":"Trotti LM","year":"2017","unstructured":"Trotti LM. Idiopathic hypersomnia. Sleep Med Clin. 2017, 12:331-44. 10.1016\/j.jsmc.2017.03.009","journal-title":"Sleep Med Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004685","article-title":"Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors","volume":"4","author":"Rye DB","year":"2012","unstructured":"Rye DB, Bliwise DL, Parker K, et al.. Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors. Sci Transl Med. 2012, 4:161ra151. 10.1126\/scitranslmed.3004685","journal-title":"Sci Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0226-9","article-title":"Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment","volume":"15","author":"Bassetti CL","year":"2019","unstructured":"Bassetti CL, Adamantidis A, Burdakov D, et al.. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019, 15:519-39. 10.1038\/s41582-019-0226-9","journal-title":"Nat Rev Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2023.101766","article-title":"Update on the treatment of idiopathic hypersomnia: progress, challenges, and expert opinion","volume":"69","author":"Arnulf I","year":"2023","unstructured":"Arnulf I, Thomas R, Roy A, Dauvilliers Y. Update on the treatment of idiopathic hypersomnia: progress, challenges, and expert opinion. Sleep Med Rev. 2023, 69:101766. 10.1016\/j.smrv.2023.101766","journal-title":"Sleep Med Rev"},{"key":"ref6","unstructured":"Idiopathic hypersomnia, understanding the often overlooked sleep disorder. (2021). Accessed. May 25, 2025: https:\/\/www.jazzpharma.com\/science_stories\/idiopathic-hypersomnia-understanding-often-overlooked-sleep-disorder."},{"key":"ref7","unstructured":"Jazz pharmaceuticals announces U.S. FDA approval of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) oral solution for idiopathic hypersomnia in adults. (2021). Accessed. May 25, 2025: https:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-announces-us-fda-approval-xyw...."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202229","article-title":"Efficacy of low-sodium oxybate in the treatment of idiopathic hypersomnia: evaluation of treatment response based on the Epworth sleepiness scale and idiopathic hypersomnia severity scale scores (S6.009)","volume":"100","author":"Rosenberg R","year":"2023","unstructured":"Rosenberg R, Chen A, Steininger TL, Macfadden W, Dauvilliers Y. Efficacy of low-sodium oxybate in the treatment of idiopathic hypersomnia: evaluation of treatment response based on the Epworth sleepiness scale and idiopathic hypersomnia severity scale scores (S6.009). Neurology. 2023, 100:1968. 10.1212\/WNL.0000000000202229","journal-title":"Neurology"},{"key":"ref9","unstructured":"How Inspire\u00ae therapy works. (2021). Accessed. June 2, 2025: https:\/\/www.inspiresleep.com\/en-us\/how-inspire-therapy-works\/."},{"article-title":"Idiopathic hypersomnia","year":"2023","key":"ref10","unstructured":"Idiopathic hypersomnia. International Classification of Sleep Disorders, Third Edition, Text Revision (ICSD-3-TR).  American Academy of Sleep Medicine, Darien, IL; 2023. 161-6."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/26.8.1006","article-title":"Prevalence of sleep-disordered breathing in children with Down syndrome: polygraphic findings in 108 children","volume":"26","author":"de Miguel-D\u00edez J","year":"2003","unstructured":"de Miguel-D\u00edez J, Villa-Asensi JR, Alvarez-Sala JL. Prevalence of sleep-disordered breathing in children with Down syndrome: polygraphic findings in 108 children. Sleep. 2003, 26:1006-9. 10.1093\/sleep\/26.8.1006","journal-title":"Sleep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2012.01.004","article-title":"DQB1*06:02 allele-specific expression varies by allelic dosage, not narcolepsy status","volume":"73","author":"Weiner Lachmi K","year":"2012","unstructured":"Weiner Lachmi K, Lin L, Kornum BR, Rico T, Lo B, Aran A, Mignot E. DQB1*06:02 allele-specific expression varies by allelic dosage, not narcolepsy status. Hum Immunol. 2012, 73:405-10. 10.1016\/j.humimm.2012.01.004","journal-title":"Hum Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/380675-xywav-a-treatment-option-for-idiopathic-hypersomnia-in-down-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T14:34:40Z","timestamp":1754318080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/380675-xywav-a-treatment-option-for-idiopathic-hypersomnia-in-down-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.89339","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}